89bio, Inc.
ETNBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ETNB. That does not mean none is planned.
Get an email about ETNB's next catalysts
Track 89bio (ETNB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Pegozafermin
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
BIO89-100
NASH - Nonalcoholic Steatohepatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pegozafermin | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | - | - |
BIO89-100 | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
1 drug in this indication
NASH - Nonalcoholic Steatohepatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in 89bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in 89bio, Inc.'s (ETNB) pipeline across Phase 3, Phase 2. Its lead program is Pegozafermin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is 89bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for 89bio, Inc. (ETNB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ETNB biotech catalysts?→
Add ETNB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow 89bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.